Lipella Pharmaceuticals Inc.
LIPO
$0.593
-$0.0002-0.03%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -7.29% | 8.88% | 19.31% | 0.77% | 35.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -7.29% | 8.88% | 19.31% | 0.77% | 35.00% |
| Cost of Revenue | 39.49% | 18.08% | 18.90% | -1.88% | -3.08% |
| Gross Profit | -49.89% | -19.70% | -18.83% | 2.38% | 8.80% |
| SG&A Expenses | 10.11% | -10.25% | -7.09% | 2.49% | 60.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.33% | 6.61% | 8.11% | -0.27% | 15.97% |
| Operating Income | -31.46% | -6.39% | -7.05% | 0.38% | -14.06% |
| Income Before Tax | -33.26% | -8.18% | -8.60% | 0.71% | -12.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.26% | -8.18% | -8.60% | 0.71% | -12.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.26% | -8.18% | -8.60% | 0.71% | -12.44% |
| EBIT | -31.46% | -6.39% | -7.05% | 0.38% | -14.06% |
| EBITDA | -31.47% | -57.10% | -143.50% | -221.14% | -- |
| EPS Basic | 30.77% | 32.77% | 23.99% | 28.26% | 12.92% |
| Normalized Basic EPS | 30.77% | 32.77% | 23.99% | 28.26% | 12.92% |
| EPS Diluted | 30.78% | 32.90% | 24.55% | 28.67% | 13.50% |
| Normalized Diluted EPS | 30.77% | 32.77% | 23.99% | 28.26% | 12.92% |
| Average Basic Shares Outstanding | 153.55% | 67.03% | 39.64% | 41.49% | 37.15% |
| Average Diluted Shares Outstanding | 153.55% | 67.03% | 39.64% | 41.49% | 37.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |